Once-Daily Pill Eases Psoriatic Arthritis Symptoms

In a late-stage trial, adults with psoriatic arthritis who took icotrokinra saw more joint improvement than those on placebo.

Updated on Nov. 7, 2026 in Arthritis

A single white oval tablet on a pale wooden counter beside a glass of water, under soft window light, representing an oral daily treatment option. — Johnson & Johnson reported that its once-daily pill icotrokinra, branded Icotyde, eased psoriatic arthritis symptoms in a 552-adult late-stage trial. AI Illustration. Upload story photo >

Live Poll

Would you trust a new once-daily pill to treat your joint pain?

Johnson & Johnson reported that its once-daily pill icotrokinra, branded Icotyde, eased symptoms of psoriatic arthritis in a late-stage trial of 552 adults who had not previously received biologic medicines. The company also reported skin improvements in psoriasis in the same study.

Why it matters

Psoriatic arthritis causes joint pain, swelling and stiffness, and it often appears in people who already have psoriasis, so a pill that addresses both conditions could widen treatment options for patients who prefer oral medication to injections. Positive results could support expanded use of the drug.

The results come from a late-stage trial of 552 adults with active psoriatic arthritis who had not previously been treated with biologics, with outcomes measured at 16 weeks against a placebo group. The 20% joint improvement rate was 58% on icotrokinra versus 41% on placebo.

The players

Johnson & Johnson

A multinational drugmaker with a major immunology franchise, and the developer and marketer of Icotyde (icotrokinra).

The details

Icotrokinra is taken as a once-daily oral pill, offering an alternative to the injectable and infused biologic medicines that are commonly used for these conditions. In the trial, efficacy was measured through tender and swollen joint counts and other measures of disease activity. Icotyde is already FDA-approved for moderate-to-severe plaque psoriasis, and the new results address its use in psoriatic arthritis.

Trial outcomes were measured over 16 weeks.
Johnson & Johnson announced the positive trial results on November 7, 2026.

Health Landscape

Icotyde's psoriasis approval already gives it a foothold in the oral treatment market for skin disease. The new results would extend that oral option to psoriatic arthritis, a condition that roughly 30% of people with psoriasis also develop.

If you have psoriasis and joint pain or swelling, this research is worth raising with your doctor, since joint symptoms can develop alongside skin disease. Any decision about changing or starting a treatment should be made with your physician, who can weigh the trial data against your own health history.

The takeaway

Oral options for psoriatic arthritis may be expanding, and the new trial suggests a once-daily pill can improve both joint and skin symptoms. If you have psoriasis, ask your doctor whether joint symptoms should be checked as part of your routine care.